

Wayne W. Fang  
LOWENSTEIN SANDLER LLP  
One Lowenstein Drive  
Roseland, New Jersey 07068  
Tel: 973.597.2500

IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF NEW JERSEY

PURDUE PHARMA L.P., PURDUE )  
PHARMACEUTICALS L.P. and )  
RHODES TECHNOLOGIES, )  
 )  
Plaintiffs, )  
v. ) C.A. No. \_\_\_\_\_  
 )  
ELITE LABORATORIES, INC. )  
and ELITE PHARMACEUTICALS, )  
INC., )  
 )  
Defendants. )  
 )

**COMPLAINT**

Plaintiffs Purdue Pharma L.P., Purdue Pharmaceuticals L.P. (collectively, “Purdue”) and Rhodes Technologies (“Rhodes”, collectively, “Plaintiffs”) for their Complaint against Defendants Elite Laboratories, Inc. and Elite Pharmaceuticals, Inc. (collectively, “Elite” or “Defendants”), aver as follows:

**LOCAL RULE 10.1(a) COMPLIANCE**

1. Plaintiff Purdue Pharma L.P. (“Purdue Pharma”) has its principal place of business at One Stamford Forum, 201 Tresser Boulevard, Stamford, Connecticut 06901-3431; Plaintiffs Purdue Pharmaceuticals L.P. (“Purdue Pharmaceuticals”) and Rhodes both have their principal place of business at 4701 International Boulevard W., Wilson, NC 27893; Defendants both have their principal place of business at 165 Ludlow Ave, Northvale, New Jersey 07647.

**NATURE OF THE ACTION**

2. This is an action for patent infringement arising under the patent laws of the United States, Title 35, United States Code, for infringement of United States Patent Nos. 9,763,933 (“the Mannion ’933 patent”); 9,770,416 (“the ’416 patent”); 9,492,389 (“the ’389 patent”); 9,492,391 (“the ’391 patent”); 9,492,392 (“the ’392 patent”); 9,492,393 (“the ’393 patent”); 9,775,808 (“the ’808 patent”); 11,304,908 (“the ’908 patent”); 11,304,909 (“the ’909 patent”); 9,073,933 (“the ’933 patent”); 9,522,919 (“the ’919 patent”); 10,407,434 (“the ’434 patent”); 9,775,811 (“the ’811 patent”); 9,763,886 (“the ’886 patent”); and 11,298,322 (“the ’322 patent”) (collectively, “the patents-in-suit”). This action relates to Abbreviated New Drug Application (“ANDA”) No. 217939 submitted, upon information and belief, in the name of Defendants to the United States Food and Drug Administration (“FDA”).

3. Plaintiffs seek judgment that Defendants have infringed the patents-in-suit, which are—with the exception of the '811 patent, the '886 patent, and the '322 patent—listed in the FDA *Approved Drug Products With Therapeutic Equivalence Evaluations* (“Orange Book”) as covering Purdue’s OxyContin® (oxycodone hydrochloride) (“OxyContin®”), an extended-release pain medication. Defendants have infringed the patents-in-suit at least under 35 U.S.C. § 271(e)(2)(A) by filing ANDA No. 217939 (“Defendants’ ANDA”), submitted, upon information and belief, in the name of Defendants to the FDA. Defendants’ ANDA seeks approval to market a generic version of Purdue’s OxyContin®, which is the subject of approved New Drug Application (“NDA”) No. 022272, in the 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg and 80 mg dosage strengths (“Defendants’ ANDA Products”). The '811 patent, the '886 patent, and the '322 patent are directed to the processes for manufacture of OxyContin®.

### **THE PARTIES**

4. Purdue Pharma is a limited partnership organized and existing under the laws of the State of Delaware. Purdue Pharma is an owner of the patents-in-suit identified in paragraphs 25-39 below. Purdue Pharma is also the holder of approved NDA No. 022272 for OxyContin®, indicated for pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative

treatment options are inadequate. Purdue Pharma sells OxyContin® in the United States.

5. Purdue Pharmaceuticals is a limited partnership organized and existing under the laws of the State of Delaware. Purdue Pharmaceuticals is an owner of the patents-in-suit, identified in paragraphs 25-39 below.

6. Rhodes is a partnership organized and existing under the laws of the State of Delaware. Rhodes is an owner of the patents directed to oxycodone with low levels of alpha, beta unsaturated ketone impurities, identified in paragraphs 34-36 below.

7. On information and belief, Defendant Elite Laboratories, Inc. (“Elite Labs”) is a company organized and existing under the laws of the State of Delaware, having a principal place of business at 165 Ludlow Ave, Northvale, New Jersey 07647.

8. On information and belief, Defendant Elite Pharmaceuticals, Inc., USA (“Elite Pharma”) is a corporation organized and existing under the laws of the State of Nevada, having a principal place of business at 165 Ludlow Ave, Northvale, New Jersey 07647.

9. On information and belief, Elite Labs is registered to do business in New Jersey as a Foreign For-Profit Corporation.

10. On information and belief, Elite Pharma is registered to do

business in New Jersey as a Foreign For-Profit Corporation.

11. On information and belief, Defendant Elite Labs is a wholly-owned subsidiary of Elite Pharma.

12. On information and belief, Defendants develop, manufacture, distribute and/or market pharmaceutical products throughout the United States, including in this judicial district, through their own actions and through the actions of their agents.

13. On information and belief, Defendants are working in concert with respect to the development, regulatory approval, marketing, sale and/or distribution of pharmaceutical products, including the Defendants' ANDA Products described in Defendants' ANDA.

14. On information and belief, Defendants closely coordinate their commercial activities and simultaneously share senior corporate officers.

15. On information and belief, Defendants were jointly involved in the preparation and submission of Defendants' ANDA.

16. On information and belief, if Defendants' ANDA is approved, Defendants will be jointly involved in the manufacturing, marketing, distributing and/or sale of Defendants' ANDA Products.

**SUBJECT MATTER JURISDICTION AND VENUE**

17. This action arises under the patent laws of the United States, including 35 U.S.C. § 271 and the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202.

18. This Court has subject matter jurisdiction pursuant to 28 U.S.C. §§ 1331 and 1338(a).

19. Venue is proper in this Court pursuant to 28 U.S.C. § 1400(b) because Defendants have a regular and established place of business in this judicial district and because Defendants have committed acts of infringement in this judicial district.

**PERSONAL JURISDICTION**

20. On information and belief, this Court has personal jurisdiction over each of the Defendants by virtue of, *inter alia*, having their principal place of business located at 165 Ludlow Ave, Northvale, New Jersey.

21. Moreover, on information and belief, this Court has personal jurisdiction over each of the Defendants by virtue of, *inter alia*, their systematic and continuous contacts with New Jersey and contacts with New Jersey in connection with the submission of Defendants' ANDA, as set forth below.

22. On information and belief, work related to Defendants' ANDA submission occurred at Defendants' principal place of business located at 165 Ludlow Ave, Northvale, New Jersey.

23. On information and belief, Defendants are in the business of preparing generic pharmaceuticals that they distribute in the State of New Jersey and throughout the United States.

24. On information and belief, if Defendants' ANDA is approved, the Defendants' ANDA Products would, among other things, be marketed and distributed in New Jersey, and/or prescribed by physicians practicing and dispensed by pharmacies located within New Jersey, all of which would have a substantial effect on New Jersey.

#### **THE PATENTS-IN-SUIT**

25. Purdue is the lawful owner of all right, title and interest in the Mannion '933 patent, titled "TAMPER RESISTANT DOSAGE FORMS," including the right to sue and to recover for past infringement thereof. The Mannion '933 patent is listed in the Orange Book as covering OxyContin®, which is the subject of approved NDA No. 022272. A copy of the Mannion '933 patent is attached hereto as Exhibit A, which was duly and legally issued on September 19, 2017, naming William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, and Haiyong H. Huang as the inventors.

26. Purdue is the lawful owner of all right, title and interest in the '416 patent, titled "TAMPER RESISTANT DOSAGE FORMS," including the right to sue and to recover for past infringement thereof. The '416 patent is listed in the Orange Book as covering OxyContin®, which is the subject of approved NDA No. 022272. A copy of the '416 patent is attached hereto as Exhibit B, which was duly and legally issued on September 26, 2017, naming William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, and Haiyong H. Huang as the inventors.

27. Purdue is the lawful owner of all right, title and interest in the '389 patent, titled "TAMPER RESISTANT DOSAGE FORMS," including the right to sue and to recover for past infringement thereof. The '389 patent is listed in the Orange Book as covering OxyContin®, which is the subject of approved NDA No. 022272. A copy of the '389 patent is attached hereto as Exhibit C, which was duly and legally issued on November 15, 2016, naming William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, and Haiyong H. Huang as the inventors.

28. Purdue is the lawful owner of all right, title and interest in the '391 patent, titled "TAMPER RESISTANT DOSAGE FORMS," including the right to sue and to recover for past infringement thereof. The '391 patent is listed in the Orange Book as covering OxyContin®, which is the subject of approved NDA No. 022272. A copy of the '391 patent is attached hereto as Exhibit D, which was duly and legally issued on November 15, 2016, naming William H. McKenna, Richard

O. Mannion, Edward P. O'Donnell, and Haiyong H. Huang as the inventors.

29. Purdue is the lawful owner of all right, title and interest in the '392 patent, titled "TAMPER RESISTANT DOSAGE FORMS," including the right to sue and to recover for past infringement thereof. The '392 patent is listed in the Orange Book as covering OxyContin®, which is the subject of approved NDA No. 022272. A copy of the '392 patent is attached hereto as Exhibit E, which was duly and legally issued on November 15, 2016, naming William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, and Haiyong H. Huang as the inventors.

30. Purdue is the lawful owner of all right, title and interest in the '393 patent, titled "TAMPER RESISTANT DOSAGE FORMS," including the right to sue and to recover for past infringement thereof. The '393 patent is listed in the Orange Book as covering OxyContin®, which is the subject of approved NDA No. 022272. A copy of the '393 patent is attached hereto as Exhibit F, which was duly and legally issued on November 15, 2016, naming William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, and Haiyong H. Huang as the inventors.

31. Purdue is the lawful owner of all right, title and interest in the '808 patent, titled "TAMPER RESISTANT DOSAGE FORMS," including the right to sue and to recover for past infringement thereof. The '808 patent is listed in the Orange Book as covering OxyContin®, which is the subject of approved NDA No. 022272. A copy of the '808 patent is attached hereto as Exhibit G, which was duly

and legally issued on October 3, 2017, naming William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, and Haiyong H. Huang as the inventors.

32. Purdue is the lawful owner of all right, title and interest in the '908 patent, titled "TAMPER RESISTANT DOSAGE FORMS," including the right to sue and to recover for past infringement thereof. The '908 patent is listed in the Orange Book as covering OxyContin®, which is the subject of approved NDA No. 022272. A copy of the '908 patent is attached hereto as Exhibit H, which was duly and legally issued on April 19, 2022, naming William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, and Haiyong H. Huang as the inventors.

33. Purdue is the lawful owner of all right, title and interest in the '909 patent, titled "TAMPER RESISTANT DOSAGE FORMS," including the right to sue and to recover for past infringement thereof. The '909 patent is listed in the Orange Book as covering OxyContin®, which is the subject of approved NDA No. 022272. A copy of the '909 patent is attached hereto as Exhibit I, which was duly and legally issued on April 19, 2022, naming William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, and Haiyong H. Huang as the inventors.

34. Plaintiffs lawfully own all right, title, and interest in the '933 patent, titled "OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PPM 14-HYDROXYCODEINONE," including the right to sue and to recover for past infringement thereof. The '933 patent is listed in the Orange Book as covering

OxyContin®, which is the subject of approved NDA No. 022272. A copy of the '933 patent is attached hereto as Exhibit J, which was duly and legally issued on July 7, 2015, naming Robert Chapman, Lonn S. Rider, Qi Hong, Donald Kyle, and Robert Kupper as the inventors.

35. Plaintiffs lawfully own all right, title, and interest in the '919 patent, titled "OXYCODONE COMPOSITIONS," including the right to sue and to recover for past infringement thereof. The '919 patent is listed in the Orange Book as covering OxyContin®, which is the subject of approved NDA No. 022272. A copy of the '919 patent is attached hereto as Exhibit K, which was duly and legally issued on December 20, 2016, naming Robert Chapman, Lonn S. Rider, Qi Hong, Donald Kyle, and Robert Kupper as the inventors.

36. Plaintiffs lawfully own all right, title, and interest in the '434 patent, titled "PROCESS FOR PREPARING OXYCODONE COMPOSITIONS," including the right to sue and to recover for past infringement thereof. The '434 patent is listed in the Orange Book as covering OxyContin®, which is the subject of approved NDA No. 022272. A copy of the '434 patent is attached hereto as Exhibit L, which was duly and legally issued on September 10, 2019, naming Robert Chapman, Lonn S. Rider, Qi Hong, Donald Kyle, and Robert Kupper as the inventors.

37. Purdue is the lawful owner of all right, title and interest in the '811 patent, titled "TAMPER RESISTANT DOSAGE FORMS," including the right to sue and to recover for past infringement thereof. A copy of the '811 patent is attached hereto as Exhibit M, which was duly and legally issued on October 3, 2017, naming William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, and Haiyong H. Huang as the inventors.

38. Purdue is the lawful owner of all right, title and interest in the '886 patent, titled "TAMPER RESISTANT DOSAGE FORMS," including the right to sue and to recover for past infringement thereof. A copy of the '886 patent is attached hereto as Exhibit N, which was duly and legally issued on September 19, 2017, naming William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, and Haiyong H. Huang as the inventors.

39. Purdue is the lawful owner of all right, title and interest in the '322 patent, titled "TAMPER RESISTANT DOSAGE FORMS," including the right to sue and to recover for past infringement thereof. A copy of the '322 patent is attached hereto as Exhibit O, which was duly and legally issued on April 12, 2022, naming William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, and Haiyong H. Huang as the inventors.

**DEFENDANTS' ANDA**

40. On information and belief, on or before September 28, 2023, Defendants filed Defendants' ANDA in the name of Defendants with the FDA, under § 505(j) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 355(j)), seeking approval to engage in the commercial manufacture, use, sale, offer for sale, or importation of Defendants' ANDA Products, generic products based on the Reference Listed Drug OxyContin®, which is the subject of approved NDA No. 022272.

41. On information and belief, Defendants subsequently submitted in their ANDA a "Paragraph IV" certification under 21 U.S.C. § 355(j)(2)(A)(vii)(IV) alleging that, *inter alia*, the patents-in-suit, listed in the Orange Book as covering OxyContin®, which is the subject of approved NDA No. 022272, are "invalid, unenforceable, and/or will not be infringed" by the commercial manufacture, use, offer for sale, sale or importation of the drug products described in Defendants' ANDA.

42. In a letter dated September 28, 2023, addressed to and received by Purdue Pharma on or about September 29, 2023, Defendants provided what purports to be a "Notice of Paragraph IV Certification" with respect to Defendants' ANDA and Defendants' ANDA Products, and the Orange Book patents, under § 505(j)(2)(B)(iv) of the Federal Food, Drug, and Cosmetic Act ("Notice Letter").

43. Defendants' submission of Defendants' ANDA was an act of infringement of the Orange Book patents under the United States Patent Law, 35 U.S.C. § 271(e)(2)(A).

44. Plaintiffs commenced this action within the 45-day period after receiving the Notice Letter as described in 21 U.S.C. § 355(j)(5)(B)(iii).

**FIRST CLAIM FOR RELIEF**  
**(PATENT INFRINGEMENT OF U.S. PATENT NO. 9,763,933)**

45. Purdue incorporates by reference and realleges paragraphs 1 through 44 above as though fully restated herein.

46. Pursuant to 35 U.S.C. § 271(e)(2), Defendants' submission of Defendants' ANDA to the FDA seeking approval of Defendants' ANDA Products was an act of infringement of the Mannion '933 patent by Defendants.

47. Defendants' ANDA Products, or the use or manufacture thereof, are covered by one or more claims of the Mannion '933 patent, including but not limited to independent claims 1 and 11, which recite, *inter alia*, a pharmaceutical composition comprising an extended-release matrix, wherein said composition comprises at least one active agent and at least one high molecular weight polyethylene oxide ("PEO") having an approximate molecular weight of 1 million to 15 million , and various claims dependent therefrom.

48. If approved by the FDA, Defendants' commercial manufacture,

use, importation, sale, and/or offer for sale of Defendants' ANDA Products will infringe, contribute to the infringement of, and/or induce the infringement of one or more claims of the Mannion '933 patent under 35 U.S.C. § 271(a)-(c). Since at least the date of the Notice Letter, Defendants have acted with knowledge, or at least with willful blindness of the fact, that the induced acts would constitute infringement of the Mannion '933 patent.

49. Defendants' ANDA Products constitute a material part of the inventions covered by the claims of the Mannion '933 patent.

50. Upon information and belief, Defendants have been aware of the existence of the Mannion '933 patent and have no reasonable basis for believing that Defendants' ANDA Products will not infringe the Mannion '933 patent, thus rendering the case "exceptional," as that term is used in 35 U.S.C. § 285.

51. Unless Defendants are enjoined by the Court, Purdue will be substantially and irreparably harmed by Defendants' infringement of the Mannion '933 patent. Purdue has no adequate remedy at law.

**SECOND CLAIM FOR RELIEF**  
**(PATENT INFRINGEMENT OF U.S. PATENT NO. 9,770,416)**

52. Purdue incorporates by reference and realleges paragraphs 1 through 51 above as though fully restated herein.

53. Pursuant to 35 U.S.C. § 271(e)(2), Defendants' submission of Defendants' ANDA to the FDA seeking approval of Defendants' ANDA Products was an act of infringement of the '416 patent by Defendants.

54. On information and belief, Defendants' ANDA Products, or use thereof, are covered by one or more claims of the '416 patent, including but not limited to independent claims 1 and 12, which recite, *inter alia*, a pharmaceutical composition comprising: at least one active agent comprising an opioid or a pharmaceutically acceptable salt, and at least one high molecular weight PEO, having an approximate molecular weight of from 1 million to 8 million; wherein (a) the active agent and high molecular weight PEO are combined in a solid oral extended-release dosage form that is (i) compression shaped, (ii) air cured by heated air, without compression, for a curing time of about 15 minutes to about 8 hours at a curing temperature of about 60° C to about 90° C, (iii) cooled, and (iv) hardened; (b) the high molecular weight PEO is at least partially melted upon curing and comprises at least about 50% (by weight) of the dosage form; (c) the active agent comprises at least about 1.3% (by weight) of the dosage form; (d) the molecular weight of each PEO is based on rheological measurements; (e) the total weight of the dosage form is calculated by excluding the combined weight of said film coatings; and (f) the dosage form is expanded upon curing, as measured by a decrease in density of at least about 1.5%, and the dosage form provides a hardness

of at least about 439 N, and various claims dependent therefrom.

55. If approved by the FDA, Defendants' commercial manufacture, use, importation, sale, and/or offer for sale of Defendants' ANDA Products will infringe, contribute to the infringement of, and/or induce the infringement of one or more claims of the '416 patent under 35 U.S.C. § 271(a)-(c). Since at least the date of the Notice Letter, Defendants have acted with knowledge, or at least with willful blindness of the fact, that the induced acts would constitute infringement of the '416 patent.

56. Defendants' ANDA Products constitute a material part of the inventions covered by the claims of the '416 patent.

57. Upon information and belief, Defendants have been aware of the existence of the '416 patent and have no reasonable basis for believing that Defendants' ANDA Products will not infringe the '416 patent, thus rendering the case "exceptional," as that term is used in 35 U.S.C. § 285.

58. Unless Defendants are enjoined by the Court, Purdue will be substantially and irreparably harmed by Defendants' infringement of the '416 patent. Purdue has no adequate remedy at law.

**THIRD CLAIM FOR RELIEF**  
**(PATENT INFRINGEMENT OF U.S. PATENT No. 9,492,389)**

59. Purdue incorporates by reference and realleges paragraphs 1 through 58 above as though fully restated herein.

60. Pursuant to 35 U.S.C. § 271(e)(2), Defendants' submission of Defendants' ANDA to the FDA seeking approval of Defendants' ANDA Products was an act of infringement of the '389 patent by Defendants.

61. Defendants' ANDA Products, or the use or manufacture thereof, are covered by one or more claims of the '389 patent, including but not limited to independent claim 1, which recites, *inter alia*, a cured shaped pharmaceutical tablet comprising at least a first compression shaped and then air cured matrix, wherein said curing is without compression, by heated air having a temperature of at least about 62° C for a duration of at least about 5 minutes, said matrix comprising oxycodone or a pharmaceutically acceptable salt thereof in combination with at least one high molecular weight PEO having an approximate molecular weight selected from the group consisting of 4,000,000, 7,000,000, and a combination thereof; wherein said high molecular weight PEO is at least 54% by weight of the total weight of the uncoated tablet, and various claims dependent therefrom.

62. If approved by the FDA, Defendants' commercial manufacture, use, importation, sale, and/or offer for sale of Defendants' ANDA Products will infringe, contribute to the infringement of, and/or induce the infringement of one or

more claims of the '389 patent under 35 U.S.C. § 271(a)-(c). Since at least the date of the Notice Letter, Defendants have acted with knowledge, or at least with willful blindness of the fact, that the induced acts would constitute infringement of the '389 patent.

63. Defendants' ANDA Products constitute a material part of the inventions covered by the claims of the '389 patent.

64. Upon information and belief, Defendants have been aware of the existence of the '389 patent and have no reasonable basis for believing that Defendants' ANDA Products will not infringe the '389 patent, thus rendering the case "exceptional," as that term is used in 35 U.S.C. § 285.

65. Unless Defendants are enjoined by the Court, Purdue will be substantially and irreparably harmed by Defendants' infringement of the '389 patent. Purdue has no adequate remedy at law.

**FOURTH CLAIM FOR RELIEF**  
**(PATENT INFRINGEMENT OF U.S. PATENT NO. 9,492,391)**

66. Purdue incorporates by reference and realleges paragraphs 1 through 65 above as though fully restated herein.

67. Pursuant to 35 U.S.C. § 271(e)(2), Defendants' submission of Defendants' ANDA to the FDA seeking approval of Defendants' ANDA Products was an act of infringement of the '391 patent by Defendants.

68. Defendants' ANDA Products, or the use thereof, are covered by

one or more claims of the '391 patent, including but not limited to independent claim 1, which recites, *inter alia*, a method of treating pain comprising administering to a patient in need thereof a pharmaceutical tablet comprising at least a first compression shaped and then air cured matrix, wherein said curing is without compression, by heated air having a temperature of at least about 62° C for a duration of at least about 5 minutes, said matrix comprising oxycodone or a pharmaceutically acceptable salt thereof in combination with at least one high molecular weight PEO having, based on rheological measurements, an approximate molecular weight selected from the group consisting of 4,000,000, 7,000,000, and a combination thereof, and various claims dependent therefrom.

69. If approved by the FDA, Defendants' commercial manufacture, use, importation, sale, and/or offer for sale of Defendants' ANDA Products will infringe, contribute to the infringement of, and/or induce the infringement of one or more claims of the '391 patent under 35 U.S.C. § 271(a)-(c). Since at least the date of the Notice Letter, Defendants have acted with knowledge, or at least with willful blindness of the fact, that the induced acts would constitute infringement of the '391 patent.

70. Defendants' ANDA Products constitute a material part of the inventions covered by the claims of the '391 patent.

71. On information and belief, Defendants know that Defendants'

ANDA Products are especially made or especially adapted for use in the infringement of one or more claims of the '391 patent.

72. On information and belief, Defendants have had and continue to have knowledge that there is no substantial non-infringing use for Defendants' ANDA Products.

73. The administration of Defendants' ANDA Products by any Healthcare Providers and patients, for the treatment of pain, will directly infringe one or more claims of the '391 patent.

74. Defendants' proposed label for Defendants' ANDA Products will explicitly instruct Healthcare Providers and patients to use Defendants' ANDA Products in a manner that will directly infringe one or more claims of the '391 patent, including but not limited to independent claim 1, which recites *inter alia*, a method of treating pain comprising administering to a patient in need thereof a pharmaceutical tablet comprising at least a first compression shaped and then air cured matrix, wherein said curing is without compression by heated air having a temperature of at least about 62° C for a duration of at least about 5 minutes, said matrix comprising oxycodone or a pharmaceutically acceptable salt thereof in combination with at least one high molecular weight PEO having, based on rheological measurements, an approximate molecular weight selected from the group consisting of 4,000,000, 7,000,000, and a combination thereof, and various

claims dependent therefrom. OxyContin® is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

75. If Defendants' ANDA Products are approved by the FDA, Defendants will actively induce others including, *e.g.*, Healthcare Providers and patients, to directly infringe one or more claims of the '391 patent. Since at least the date of the Notice Letter, Defendants have acted with knowledge, or at least with willful blindness of the fact, that the induced acts would constitute infringement of the '391 patent.

76. Defendants intend to cause direct infringement by others, *e.g.*, Healthcare Providers and patients.

77. If Defendants' ANDA Products are approved by the FDA, Defendants will take affirmative steps to induce infringement by, among other things, instructing Healthcare Providers and patients, through Defendants' proposed label, to use Defendants' ANDA Products in a manner that directly infringes one or more claims of the '391 patent. Thus, Defendants will aid, abet, urge, or encourage others including, *e.g.*, Healthcare Providers and patients, to directly infringe one or more claims of the '391 patent, and Defendants will affirmatively and specifically intend to cause direct infringement.

78. Upon information and belief, Defendants have been aware of the

existence of the '391 patent and have no reasonable basis for believing that Defendants' ANDA Products will not infringe the '391 patent, thus rendering the case "exceptional," as that term is used in 35 U.S.C. § 285.

79. Unless Defendants are enjoined by the Court, Purdue will be substantially and irreparably harmed by Defendants' infringement of the '391 patent. Purdue has no adequate remedy at law.

**FIFTH CLAIM FOR RELIEF**  
**(PATENT INFRINGEMENT OF U.S. PATENT NO. 9,492,392)**

80. Purdue incorporates by reference and realleges paragraphs 1 through 79 above as though fully restated herein.

81. Pursuant to 35 U.S.C. § 271(e)(2), Defendants' submission of Defendants' ANDA to the FDA seeking approval of Defendants' ANDA Products was an act of infringement of the '392 patent by Defendants.

82. Defendants' ANDA Products, or the use or manufacture thereof, are covered by one or more claims of the '392 patent, including but not limited to independent claim 1, which recites, *inter alia*, a cured shaped pharmaceutical tablet comprising at least a first compression shaped and then air cured matrix, wherein said curing is without compression, by heated air having a temperature of at least about 62° C for a duration of at least about 5 minutes, said matrix comprising oxycodone or a pharmaceutically acceptable salt thereof in combination with at least

one high molecular weight PEO having an approximate molecular weight selected from the group consisting of 4,000,000, 7,000,000, and a combination thereof, and various claims dependent therefrom.

83. If approved by the FDA, Defendants' commercial manufacture, use, importation, sale, and/or offer for sale of Defendants' ANDA Products will infringe, contribute to the infringement of, and/or induce the infringement of one or more claims of the '392 patent under 35 U.S.C. § 271(a)-(c). Since at least the date of the Notice Letter, Defendants have acted with knowledge, or at least with willful blindness of the fact, that the induced acts would constitute infringement of the '392 patent.

84. Defendants' ANDA Products constitute a material part of the inventions covered by the claims of the '392 patent.

85. Upon information and belief, Defendants have been aware of the existence of the '392 patent and have no reasonable basis for believing that Defendants' ANDA Products will not infringe the '392 patent, thus rendering the case "exceptional," as that term is used in 35 U.S.C. § 285.

86. Unless Defendants are enjoined by the Court, Purdue will be substantially and irreparably harmed by Defendants' infringement of the '392 patent. Purdue has no adequate remedy at law.

**SIXTH CLAIM FOR RELIEF**  
**(PATENT INFRINGEMENT OF U.S. PATENT No. 9,492,393)**

87. Purdue incorporates by reference and realleges paragraphs 1 through 86 above as though fully restated herein.

88. Pursuant to 35 U.S.C. § 271(e)(2), Defendants' submission of Defendants' ANDA to the FDA seeking approval of Defendants' ANDA Products was an act of infringement of the '393 patent by Defendants.

89. Defendants' ANDA Products, or the use thereof, are covered by one or more claims of the '393 patent, including but not limited to independent claim 1, which recites *inter alia*, a method of treating pain comprising administering to a patient in need thereof a pharmaceutical tablet comprising at least a first compression shaped and then air cured matrix, wherein said curing is without compression by heated air having a temperature of at least about 62° C for a duration of at least about 5 minutes, said matrix comprising oxycodone or a pharmaceutically acceptable salt thereof in combination with at least one high molecular weight PEO having, based on rheological measurements, an approximate molecular weight selected from the group consisting of 4,000,000, 7,000,000, and a combination thereof, and various claims dependent therefrom.

90. If approved by the FDA, Defendants' commercial manufacture, use, importation, sale, and/or offer for sale of Defendants' ANDA Products will infringe, contribute to the infringement of, and/or induce the infringement of one or

more claims of the '393 patent under 35 U.S.C. § 271(a)-(c). Since at least the date of the Notice Letter, Defendants have acted with knowledge, or at least with willful blindness of the fact, that the induced acts would constitute infringement of the '393 patent.

91. Defendants' ANDA Products constitute a material part of the inventions covered by the claims of the '393 patent.

92. On information and belief, Defendants know that Defendants' ANDA Products are especially made or especially adapted for use in the infringement of one or more claims of the '393 patent.

93. On information and belief, Defendants have had and continue to have knowledge that there is no substantial non-infringing use for Defendants' ANDA Products.

94. The administration of Defendants' ANDA Products by any Healthcare Providers and patients, for the treatment of pain, will directly infringe one or more claims of the '393 patent.

95. Defendants' proposed label for Defendants' ANDA Products will explicitly instruct Healthcare Providers and patients to use Defendants' ANDA Products in a manner that will directly infringe one or more claims of the '391 patent, including but not limited to independent claim 1, which recites *inter alia*, a method of treating pain comprising administering to a patient in need thereof a

pharmaceutical tablet comprising at least a first compression shaped and then air cured matrix, wherein said curing is without compression by heated air having a temperature of at least about 62° C for a duration of at least about 5 minutes, said matrix comprising oxycodone or a pharmaceutically acceptable salt thereof in combination with at least one high molecular weight PEO having, based on rheological measurements, an approximate molecular weight selected from the group consisting of 4,000,000, 7,000,000, and a combination thereof, and various claims dependent therefrom. OxyContin® is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

96. If Defendants' ANDA Products are approved by the FDA, Defendants will actively induce others including, *e.g.*, Healthcare Providers and patients, to directly infringe one or more claims of the '393 patent. Since at least the date of the Notice Letter, Defendants have acted with knowledge, or at least with willful blindness of the fact, that the induced acts would constitute infringement of the '393 patent.

97. Defendants intend to cause direct infringement by others, *e.g.*, Healthcare Providers and patients.

98. If Defendants' ANDA Products are approved by the FDA, Defendants will take affirmative steps to induce infringement by, among other

things, instructing Healthcare Providers and patients, through Defendants' proposed label, to use Defendants' ANDA Products in a manner that directly infringes one or more claims of the '393 patent. Thus, Defendants will aid, abet, urge, or encourage others including, *e.g.*, Healthcare Providers and patients, to directly infringe one or more claims of the '393 patent, and Defendants will affirmatively and specifically intend to cause direct infringement.

99. Upon information and belief, Defendants have been aware of the existence of the '393 patent and have no reasonable basis for believing that Defendants' ANDA Products will not infringe the '393 patent, thus rendering the case "exceptional," as that term is used in 35 U.S.C. § 285.

100. Unless Defendants are enjoined by the Court, Purdue will be substantially and irreparably harmed by Defendants' infringement of the '393 patent. Purdue has no adequate remedy at law.

**SEVENTH CLAIM FOR RELIEF**  
**(PATENT INFRINGEMENT OF U.S. PATENT NO. 9,775,808)**

101. Purdue incorporates by reference and realleges paragraphs 1 through 100 above as though fully restated herein.

102. Pursuant to 35 U.S.C. § 271(e)(2), Defendants' submission of Defendants' ANDA to the FDA seeking approval of Defendants' ANDA Products was an act of infringement of the '808 patent by Defendants.

103. Defendants' ANDA Products, or the use or manufacture thereof, are covered by one or more claims of the '808 patent, including but not limited to independent claims 1 and 11, which recite *inter alia*, a pharmaceutical composition comprising at least one active agent comprising oxycodone or a pharmaceutically acceptable salt thereof; at least one high molecular weight PEO, having an approximate molecular weight of from 1 million to 15 million; and at least one of an additive and a film coating wherein (a) the active agent and high molecular weight PEO are combined in a solid oral extended-release dosage form that is (i) compression shaped, (ii) air cured by heated air, without compression, for at least about 5 minutes at a temperature above the softening temperature of the high molecular weight PEO, (iii) cooled, and (iv) hardened; (b) the high molecular weight PEO is at least partially melted upon curing and comprises at least about 30% (by weight) of the dosage form; (c) the molecular weight of each PEO is based on rheological measurements; and (d) the total weight of the dosage form is calculated by excluding the combined weight of said film coatings, and various claims dependent therefrom.

104. If approved by the FDA, Defendants' commercial manufacture, use, importation, sale, and/or offer for sale of Defendants' ANDA Products will infringe, contribute to the infringement of, and/or induce the infringement of one or more claims of the '808 patent under 35 U.S.C. § 271(a)-(c). Since at least the date

of the Notice Letter, Defendants have acted with knowledge, or at least with willful blindness of the fact, that the induced acts would constitute infringement of the '808 patent.

105. Defendants' ANDA Products constitute a material part of the inventions covered by the claims of the '808 patent.

106. Upon information and belief, Defendants have been aware of the existence of the '808 patent and have no reasonable basis for believing that Defendants' ANDA Products will not infringe the '808 patent, thus rendering the case "exceptional," as that term is used in 35 U.S.C. § 285.

107. Unless Defendants are enjoined by the Court, Purdue will be substantially and irreparably harmed by Defendants' infringement of the '808 patent. Purdue has no adequate remedy at law.

**EIGHTH CLAIM FOR RELIEF**  
**(PATENT INFRINGEMENT OF U.S. PATENT No. 11,304,908)**

108. Purdue incorporates by reference and realleges paragraphs 1 through 107 above as though fully restated herein.

109. Pursuant to 35 U.S.C. § 271(e)(2), Defendants' submission of Defendants' ANDA to the FDA seeking approval of Defendants' ANDA Products was an act of infringement of the '908 patent by Defendants.

110. Defendants' ANDA Products, or the use or manufacture thereof,

are covered by one or more claims of the '908 patent, including but not limited to independent claims 1 and 21, which recite, *inter alia*, a solid oral extended-release pharmaceutical dosage form, comprising a shaped, convection heated, and cooled extended release matrix, wherein said matrix comprises at least one PEO having, based on rheological measurements, an approximate molecular weight of at least 800,000, and at least one opioid analgesic, and wherein the shaped matrix is convection heated to a certain temperature for a certain time period and thereafter cooled, and a plurality of convection heated particles of PEO adhere to or fuse with each other within the matrix, and various claims dependent therefrom.

111. If approved by the FDA, Defendants' commercial manufacture, use, importation, sale, and/or offer for sale of Defendants' ANDA Products will infringe, contribute to the infringement of, and/or induce the infringement of one or more claims of the '908 patent under 35 U.S.C. § 271(a)-(c). Since at least the date of the Notice Letter, Defendants have acted with knowledge, or at least with willful blindness of the fact, that the induced acts would constitute infringement of the '908 patent.

112. Defendants' ANDA Products constitute a material part of the inventions covered by the claims of the '908 patent.

113. Upon information and belief, Defendants have been aware of the existence of the '908 patent and have no reasonable basis for believing that

Defendants' ANDA Products will not infringe the '908 patent, thus rendering the case "exceptional," as that term is used in 35 U.S.C. § 285.

114. Unless Defendants are enjoined by the Court, Purdue will be substantially and irreparably harmed by Defendants' infringement of the '908 patent. Purdue has no adequate remedy at law.

**NINTH CLAIM FOR RELIEF**  
**(PATENT INFRINGEMENT OF U.S. PATENT No. 11,304,909)**

115. Purdue incorporates by reference and realleges paragraphs 1 through 114 above as though fully restated herein.

116. Pursuant to 35 U.S.C. § 271(e)(2), Defendants' submission of Defendants' ANDA to the FDA seeking approval of Defendants' ANDA Products was an act of infringement of the '909 patent by Defendants.

117. Defendants' ANDA Products, or the use thereof, are covered by one or more claims of the '909 patent, including but not limited to independent claims 1 and 21, which recite, *inter alia*, a method of treating pain comprising administering to a patient in need thereof a solid oral extended release pharmaceutical dosage form, comprising a shaped, convection heated, and cooled extended release matrix, wherein said matrix comprises at least one PEO having, based on rheological measurements, an approximate molecular weight of at least 800,000, and at least one opioid analgesic, and wherein the shaped matrix is

convection heated to a certain temperature for a certain time period and thereafter cooled, and a plurality of convection heated particles of PEO adhere to or fuse with each other within the matrix, and various claims dependent therefrom.

118. If approved by the FDA, Defendants' commercial manufacture, use, importation, sale, and/or offer for sale of Defendants' ANDA Products will infringe, contribute to the infringement of, and/or induce the infringement of one or more claims of the '909 patent under 35 U.S.C. § 271(a)-(c). Since at least the date of the Notice Letter, Defendants have acted with knowledge, or at least with willful blindness of the fact, that the induced acts would constitute infringement of the '909 patent.

119. Defendants' ANDA Products constitute a material part of the inventions covered by the claims of the '909 patent.

120. Upon information and belief, Defendants know that Defendants' ANDA Products are especially made or especially adapted for use in the infringement of one or more claims of the '909 patent.

121. Upon information and belief, Defendants have had and continue to have knowledge that there is no substantial non-infringing use for Defendants' ANDA Products.

122. The administration of Defendants' ANDA Products by any Healthcare Providers and patients, for the treatment of pain, will directly infringe

one or more claims of the '909 patent.

123. Defendants' proposed label for Defendants' ANDA Products will explicitly instruct Healthcare Providers and patients to use Defendants' ANDA Products in a manner that will directly infringe one or more claims of the '909 patent, including but not limited to independent claims 1 and 21, which recite, *inter alia*, a method of treating pain comprising administering to a patient in need thereof a solid oral extended release pharmaceutical dosage form, comprising a shaped, convection heated, and cooled extended release matrix, wherein said matrix comprises at least one PEO having, based on rheological measurements, an approximate molecular weight of at least 800,000, and at least one opioid analgesic, and wherein the shaped matrix is convection heated to a certain temperature for a certain time period and thereafter cooled, and a plurality of convection heated particles of PEO adhere to or fuse with each other within the matrix, and various claims dependent therefrom.

124. If Defendants' ANDA Products are approved by the FDA, Defendants will actively induce others, including, *e.g.*, Healthcare Providers and patients, to directly infringe one or more claims of the '909 patent. Since at least the date of the Notice Letter, Defendants have acted with knowledge, or at least with willful blindness of the fact, that the induced acts would constitute infringement of the '909 patent.

125. Defendants intend to cause direct infringement by others, *e.g.*, Healthcare Providers and patients.

126. If Defendants' ANDA Products are approved by the FDA, Defendants will take affirmative steps to induce infringement by, among other things, instructing Healthcare Providers and patients, through Defendants' proposed label, to use Defendants' ANDA Products in a manner that directly infringes one or more claims of the '909 patent. Thus, Defendants will aid, abet, urge, or encourage others, including, *e.g.*, Healthcare Providers and patients, to directly infringe one or more claims of the '909 patent, and Defendants will affirmatively and specifically intend to cause direct infringement.

127. Upon information and belief, Defendants have been aware of the existence of the '909 patent and have no reasonable basis for believing that Defendants' ANDA Products will not infringe the '909 patent, thus rendering the case "exceptional," as that term is used in 35 U.S.C. § 285.

128. Unless Defendants are enjoined by the Court, Purdue will be substantially and irreparably harmed by Defendants' infringement of the '909 patent. Purdue has no adequate remedy at law.

**TENTH CLAIM FOR RELIEF**  
**(PATENT INFRINGEMENT OF U.S. PATENT No. 9,073,933)**

129. Plaintiffs incorporate by reference and reallege paragraphs 1 through 128 above as though fully restated herein.

130. Pursuant to 35 U.S.C. § 271(e)(2), Defendants' submission of Defendants' ANDA to the FDA seeking approval of Defendants' ANDA Products was an act of infringement of the '933 patent by Defendants.

131. On information and belief, the process for making the oxycodone HCl active pharmaceutical ingredient ("API") that Defendants intend to use in Defendants' ANDA Products is covered by one or more claims of the '933 patent, including but not limited to independent claim 10, which recites, *inter alia*, a process of preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone, and various claims dependent therefrom.

132. Defendants' ANDA Products, or the use or manufacture thereof, are covered by one or more claims of the '933 patent, including but not limited to independent claims 1 and 16, which recite, *inter alia*, an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone, and various claims dependent therefrom.

133. If approved by the FDA, Defendants' commercial manufacture, use, importation, sale, and/or offer for sale of Defendants' ANDA Products will infringe, contribute to the infringement of, and/or induce the infringement of one or

more claims of the '933 patent under 35 U.S.C. § 271(a)-(c). Since at least the date of the Notice Letter, Defendants have acted with knowledge, or at least with willful blindness of the fact, that the induced acts would constitute infringement of the '933 patent.

134. If approved by the FDA, Defendants' importation, offer for sale, sale, and/or use of the oxycodone HCl API in Defendants' ANDA Products will infringe one or more claims of the '933 patent under 35 U.S.C. § 271(g).

135. Defendants' ANDA Products constitute a material part of the inventions covered by the claims of the '933 patent.

136. Upon information and belief, Defendants have been aware of the existence of the '933 patent and have no reasonable basis for believing that Defendants' ANDA Products will not infringe the '933 patent, thus rendering the case "exceptional," as that term is used in 35 U.S.C. § 285.

137. Unless Defendants are enjoined by the Court, Plaintiffs will be substantially and irreparably harmed by Defendants' infringement of the '933 patent. Plaintiffs have no adequate remedy at law.

**ELEVENTH CLAIM FOR RELIEF**  
**(PATENT INFRINGEMENT OF U.S. PATENT No. 9,522,919)**

138. Plaintiffs incorporate by reference and reallege paragraphs 1 through 137 above as though fully restated herein.

139. Pursuant to 35 U.S.C. § 271(e)(2), Defendants' submission of Defendants' ANDA Defendants' ANDA to the FDA seeking approval of Defendants' ANDA Products was an act of infringement of the '919 patent by Defendants.

140. Defendants' ANDA Products, or the use or manufacture thereof, are covered by one or more claims of the '919 patent, including but not limited to independent claims 1, 12, and 18, which recite, *inter alia*, an oxycodone hydrochloride composition having a ratio of 8 $\alpha$ ,14-dihydroxy-7,8-dihydrocodeinone ("8 $\alpha$ ") to oxycodone HCl that is 0.04% or less as measured by HPLC, and various claims dependent therefrom.

141. If approved by the FDA, Defendants' commercial manufacture, use, importation, sale, and/or offer for sale of Defendants' ANDA Products will infringe, contribute to the infringement of, and/or induce the infringement of one or more claims of the '919 patent under 35 U.S.C. § 271(a)-(c). Since at least the date of the Notice Letter, Defendants have acted with knowledge, or at least with willful blindness of the fact, that the induced acts would constitute infringement of the '919 patent.

142. Defendants' ANDA Products constitute a material part of the inventions covered by the claims of the '919 patent.

143. Upon information and belief, Defendants have been aware of the existence of the '919 patent and have no reasonable basis for believing that Defendants' ANDA Products will not infringe the '919 patent, thus rendering the case "exceptional," as that term is used in 35 U.S.C. § 285.

144. Unless Defendants are enjoined by the Court, Plaintiffs will be substantially and irreparably harmed by Defendants' infringement of the '919 patent. Plaintiffs have no adequate remedy at law.

**TWELFTH CLAIM FOR RELIEF**  
**(PATENT INFRINGEMENT OF U.S. PATENT No. 10,407,434)**

145. Plaintiffs incorporate by reference and reallege paragraphs 1 through 144 above as though fully restated herein.

146. Pursuant to 35 U.S.C. § 271(e)(2), Defendants' submission of Defendants' ANDA to the FDA seeking approval of Defendants' ANDA Products was an act of infringement of the '434 patent by Defendants.

147. On information and belief, the process for making the oxycodone HCl API that Defendants intend to use in Defendants' ANDA Products is covered by one or more claims of the '434 patent, including but not limited to independent claim 1, which recites, *inter alia*, a process of purifying oxycodone free base or

oxycodone HCl that contains 8 $\alpha$ , and various claims dependent therefrom.

148. Defendants' ANDA Products, or the use or manufacture thereof, are covered by one or more claims of the '434 patent, including but not limited to dependent claim 20, which recites, *inter alia*, purified oxycodone HCl prepared according to the process recited in dependent claim 2, which recites, *inter alia*, the process of independent claim 1 as well as specific ratios of 8 $\alpha$  or HCl salt thereof to oxycodone free base or oxycodone HCl at certain stages in the claimed process.

149. If approved by the FDA, Defendants' commercial manufacture, use, importation, sale, and/or offer for sale of Defendants' ANDA Products will infringe, contribute to the infringement of, and/or induce the infringement of one or more claims of the '434 patent under 35 U.S.C. § 271(a)-(c).

150. If approved by the FDA, Defendants' importation, offer for sale, sale, and/or use of the oxycodone HCl API in Defendants' ANDA Products will infringe one or more claims of the '434 patent under 35 U.S.C. § 271(g).

151. Defendants' ANDA Products constitute a material part of the inventions covered by the claims of the '434 patent.

152. On information and belief, Defendants have been aware of the existence of the '434 patent and have no reasonable basis for believing that Defendants' ANDA Products will not infringe the '434 patent, thus rendering the case "exceptional," as that term is used in 35 U.S.C. § 285.

153. Unless Defendants are enjoined by the Court, Plaintiffs will be substantially and irreparably harmed by Defendants' infringement of the '434 patent. Plaintiffs have no adequate remedy at law.

**THIRTEENTH CLAIM FOR RELIEF**  
**(PATENT INFRINGEMENT OF U.S. PATENT NO. 9,775,811)**

154. Purdue incorporates by reference and realleges paragraphs 1 through 153 above as though fully restated herein.

155. Pursuant to 35 U.S.C. § 271(e)(2), Defendants' submission of Defendants' ANDA to the FDA seeking approval of Defendants' ANDA Products was an act of infringement of the '811 patent by Defendants.

156. On information and belief, the process for making Defendants' ANDA Products is covered by one or more claims of the '811 patent, including but not limited to independent claims 1 and 11, which recites, *inter alia*, a method of producing a plurality of extended release pharmaceutical dosages and tablets comprising the steps of: mixing an active agent comprising oxycodone or a pharmaceutically acceptable salt thereof, and at least one high molecular weight PEO, having an approximate molecular weight of from 1 million to 8 million to provide a PEO composition; compressing the PEO composition to provide a plurality of shaped matrix compositions; curing the shaped matrix compositions by exposure to heated air at a curing temperature that is at least about 60° C for a curing

time of at least about 10 minutes, to provide a plurality of cured matrix compositions; cooling the cured matrix compositions; combining any of the matrix compositions with at least one additive, before or after curing; wherein the molecular weight of each PEO is based on rheological measurements; the high molecular weight PEO comprises at least about 30% (by weight) of each dosage form or at least about 50% (by weight) of each tablet; the active agent for dosage forms comprises at least about 2.4% (by weight) of each dosage form or at least about 5% (by weight); the total weight is calculated by excluding the combined weight of film coatings; and each cured matrix composition comprises a solid oral pharmaceutical dosage form that provides an extended release of at least one active agent, and various claims dependent therefrom.

157. On information and belief, Defendants' ANDA Products, or the use or manufacture thereof, are covered by one or more claims of the '811 patent.

158. If approved by the FDA, Defendants' commercial manufacture, use, importation, sale, and/or offer for sale of Defendants' ANDA Products will infringe, contribute to the infringement of, and/or induce the infringement of one or more claims of the '811 patent under 35 U.S.C. § 271(a)-(c).

159. If approved by the FDA, Defendants' importation, offer for sale, sale, and/or use of the oxycodone HCl API in Defendants' ANDA Products will infringe one or more claims of the '811 patent under 35 U.S.C. § 271(g).

160. Defendants' ANDA Products constitute a material part of the inventions covered by the claims of the '811 patent.

161. On information and belief, Defendants have been aware of the existence of the '811 patent and have no reasonable basis for believing that Defendants' ANDA Products will not infringe the '811 patent, thus rendering the case "exceptional," as that term is used in 35 U.S.C. § 285.

162. Unless Defendants are enjoined by the Court, Purdue will be substantially and irreparably harmed by Defendants' infringement of the '811 patent. Purdue has no adequate remedy at law.

**FOURTEENTH CLAIM FOR RELIEF**  
**(PATENT INFRINGEMENT OF U.S. PATENT No. 9,773,886)**

163. Purdue incorporates by reference and realleges paragraphs 1 through 162 above as though fully restated herein.

164. Pursuant to 35 U.S.C. § 271(e)(2), Defendants' submission of Defendants' ANDA to the FDA seeking approval of Defendants' ANDA Products was an act of infringement of the '886 patent by Defendants.

165. On information and belief, the method for making Defendants' ANDA Products is covered by one or more claims of the '886 patent, including but not limited to independent claims 1 and 11, which recite, *inter alia*, a method of producing a plurality of solid oral extended release pharmaceutical dosages and

tablets comprising the steps of: mixing an active agent comprising mixing at least one active agent (in the tablet form, the agent comprises an opioid or pharmaceutically acceptable salt thereof) and at least one high molecular weight PEO, having an approximate molecular weight of from 1 million to 15 million to provide a PEO composition; compressing the PEO composition to provide a plurality of shaped matrix compositions; curing the shaped matrix compositions by exposure to heated air at a curing temperature that is at least PEO's softening temperature for a curing time of at least about 5 minutes, to provide a plurality of cured matrix compositions; cooling the cured matrix compositions; wherein the molecular weight of each PEO is based on rheological measurements; the high molecular weight PEO comprises at least about 30% (by weight) of each dosage form generally or at least about 50% (by weight) of each tablet; the total weight is calculated by excluding the combined weight of film coatings; and each cured matrix composition comprises a solid oral pharmaceutical dosage form that provides an extended release of at least one active agent, and various claims dependent therefrom. Defendants' ANDA Products, or the use or manufacture thereof, are covered by one or more claims of the '886 patent.

166. If approved by the FDA, Defendants' commercial manufacture, use, importation, sale, and/or offer for sale of Defendants' ANDA Products will infringe, contribute to the infringement of, and/or induce the infringement of one or

more claims of the '886 patent under 35 U.S.C. § 271(a)-(c).

167. If approved by the FDA, Defendants' importation, offer for sale, sale, and/or use of the oxycodone HCl API in Defendants' ANDA Products will infringe one or more claims of the '886 patent under 35 U.S.C. § 271(g).

168. Defendants' ANDA Products constitute a material part of the inventions covered by the claims of the '886 patent.

169. On information and belief, Defendants have been aware of the existence of the '886 patent and have no reasonable basis for believing that Defendants' ANDA Products will not infringe the '886 patent, thus rendering the case "exceptional," as that term is used in 35 U.S.C. § 285.

170. Unless Defendants are enjoined by the Court, Purdue will be substantially and irreparably harmed by Defendants' infringement of the '886 patent. Purdue has no adequate remedy at law.

**FIFTEENTH CLAIM FOR RELIEF**  
**(PATENT INFRINGEMENT OF U.S. PATENT No. 11,298,322)**

171. Purdue incorporates by reference and realleges paragraphs 1 through 171 above as though fully restated herein.

172. Pursuant to 35 U.S.C. § 271(e)(2), Defendants' submission of Defendants' ANDA to the FDA seeking approval of Defendants' ANDA Products was an act of infringement of the '322 patent by Defendants.

173. On information and belief, the process for making Defendants' ANDA Products is covered by one or more claims of the '322 patent, including but not limited to independent claim 1, which recites, *inter alia*, a process of preparing a solid oral extended release pharmaceutical dosage form comprising the steps of: combining at least one PEO having an approximate molecular weight of at least 800,000, and at least one opioid analgesic, to form a composition; shaping the composition to form an extended release matrix formulation; subsequently heating said extended release matrix formulation by subjecting the extended release matrix formulation to an elevated temperature that is at least the softening temperature of PEO for a time period of at least about 1 minute; and cooling the heated extended release matrix formulation, and various claims dependent therefrom.

174. On information and belief, the process for making Defendants' ANDA Products is covered by one or more claims of the '322 patent, including but not limited to independent claim 21, which recites, *inter alia*, a process of preparing a solid oral extended release pharmaceutical dosage form comprising the steps of: combining at least one PEO having an approximate molecular weight of at least 800,000, and at least one opioid analgesic, to form a composition wherein PEO is at least about 15% (by weight) of the composition; shaping the composition to form a plurality extended release matrix formulation; subsequently subjecting tablets to an elevated temperature of at least about 55° C for a time period of at least about 15

minutes; and cooling the tablets at a temperature below 50° C, and various claims dependent therefrom.

175. Defendants' ANDA Products, or the use or manufacture thereof, are covered by one or more claims of the '322 patents.

176. If approved by the FDA, Defendants' commercial manufacture, use, importation, sale, and/or offer for sale of Defendants' ANDA Products will infringe, contribute to the infringement of, and/or induce the infringement of one or more claims of the '322 patent under 35 U.S.C. § 271(a)-(c).

177. If approved by the FDA, Defendants' importation, offer for sale, sale, and/or use of the oxycodone HCl API in Defendants' ANDA Products will infringe one or more claims of the '322 patent under 35 U.S.C. § 271(g).

178. Defendants' ANDA Products constitute a material part of the inventions covered by the claims of the '322 patent.

179. On information and belief, Defendants have been aware of the existence of the '322 patent and have no reasonable basis for believing that Defendants' ANDA Products will not infringe the '322 patent, thus rendering the case "exceptional," as that term is used in 35 U.S.C. § 285.

180. Unless Defendants are enjoined by the Court, Purdue will be substantially and irreparably harmed by Defendants' infringement of the '322 patent. Purdue has no adequate remedy at law.

**PRAYER FOR RELIEF**

WHEREFORE, Plaintiffs pray for judgment as follows:

A. Find that Defendants have infringed one or more claims of each of the patents-in-suit, and that the commercial sale, offer for sale, use, importation, and/or manufacture of Defendants' ANDA Products would infringe, induce infringement of, and/or contribute to the infringement of one or more claims of each of the patents-in-suit;

B. Find, pursuant to 35 U.S.C. § 271(e)(4)(A), the effective date of any approval of Defendants' ANDA and Defendants' ANDA Products, under § 505(j) of the Federal Food, Drug and Cosmetic Act (21 U.S.C. § 355(j)), to be a date not earlier than the last date of expiration of the patents-in-suit, plus any additional periods of extension or exclusivity attached thereto;

C. Preliminarily and permanently enjoining, pursuant to 35 U.S.C. §§ 271(e)(4)(B) and 283 and Fed. R. Civ. P. 65, Defendants, their officers, partners, agents, servants, employees, parents, subsidiaries, divisions, affiliate corporations, other related business entities, and all other persons acting in concert, participation, or in privity with them, and their successors and assigns, from any commercial manufacture, use, offer to sell, or sale within the United States, or importation into the United States, of any drug product that is the subject of Defendants' ANDA,

including Defendants' ANDA Products or any other drug product that infringes the patents-in-suit;

D. Declare this an exceptional case and award Plaintiffs their attorneys' fees and costs, as provided by 35 U.S.C. §§ 271(e)(4) and 285; and

E. Award Plaintiffs such other and further relief as this Court may deem just and proper.

s/ Wayne W. Fang  
Wayne W. Fang  
Freda L. Wolfson  
LOWENSTEIN SANDLER LLP  
One Lowenstein Drive  
Roseland, New Jersey 07068  
Tel: 973.597.2500  
Fax: 973.597.2400

*Attorneys for Plaintiffs*

OF COUNSEL:

John J. Normile  
Gasper J. LaRosa  
Kevin V. McCarthy  
Jones Day  
250 Vesey Street  
New York, NY 10281-1047  
(212) 326-3777

Pablo D. Handler  
Potomac Law Group  
1177 Avenue of the Americas, 5th Floor  
New York NY 10036  
(914) 893-6883

*Attorneys for Plaintiffs*

November 9, 2023